Radiological Imaging Technology, Inc. (RIT) is an industry-leading manufacturer of quality assurance software solutions in medical physics. RIT is committed to quality, excellence, and innovation in our products, and continues to lead the dosimetry market with 31 U.S. and international patents on our QA routines. For our team, we seek motivated and goal-oriented individuals comfortable with working in a rapidly evolving, highly technical environment for positions at our corporate headquarters in Colorado Springs, CO. In the fight against cancer, our dedicated and talented team develops QA software solutions focused on improving patient safety and treatment efficacy. Join our team!
Join a recognized industry leader with a proven track record. Make a difference in the lives of cancer patients. RIT is a privately held small business founded in 1993. RIT is recognized as a leading innovator in precision automated Quality Assurance (QA) and Quality Control (QC) for medical imaging in Radiation Therapy and Diagnostic Imaging. Medical Physicists use RIT software in more than 2500 hospitals, including 47 of the Top 50 US Cancer Treatment Hospitals and in 50 countries worldwide. RIT continues to lead the market in innovation and holds many US and international patents on our QA and QC routines.
RIT was founded in 1993 by Daniel M. Ritt and Ellen Miller Ritt. RIT received FDA clearance on RIT113 radiation therapy film dosimetry that year and sold their first system soon thereafter. RIT113's revolutionary innovations provided clinical and research physicists with the first high precision automated QA tool for advanced radiation therapies. RIT quickly became recognized as the leading innovator in precision automated QA, developing the first automated IMRT analysis, which was used by the first commercial IMRT Treatment Planning System manufacturer to document and verify IMRT Dose delivery for its' FDA application.
RIT's QA analysis provides clinical physicists with the tools necessary to analyze advanced cancer treatments, thereby participating in the rapid availability of this treatment.